UA6344A1 - Спосіб одержання бензолсульфонатної солі 3-етіл-5метілового ефіру 2-(2-аміноетоксіметіл)-4-(2-хлорфеніл)-6-метіл-1,4-дігідропірідін-3,5-дікарбонової кислоти - Google Patents

Спосіб одержання бензолсульфонатної солі 3-етіл-5метілового ефіру 2-(2-аміноетоксіметіл)-4-(2-хлорфеніл)-6-метіл-1,4-дігідропірідін-3,5-дікарбонової кислоти

Info

Publication number
UA6344A1
UA6344A1 UA4202353A UA4202353A UA6344A1 UA 6344 A1 UA6344 A1 UA 6344A1 UA 4202353 A UA4202353 A UA 4202353A UA 4202353 A UA4202353 A UA 4202353A UA 6344 A1 UA6344 A1 UA 6344A1
Authority
UA
Ukraine
Prior art keywords
methyl
aminoethoxymethyl
dihydropyridine
chlorophenyl
ethyl
Prior art date
Application number
UA4202353A
Other languages
English (en)
Russian (ru)
Inventor
Девісон Едвард
Інграм Веллс Джеймс
Original Assignee
Пфайзер Лімітед
Пфайзер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA6344(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Лімітед, Пфайзер Лимитед filed Critical Пфайзер Лімітед
Publication of UA6344A1 publication Critical patent/UA6344A1/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

3-етил-5-метиловий ефір 2-(2-аміноетоксиметил) -4- (2-хлорфеніл) -6-метил-1,4-дигідропіридин-3,5-дикарбонової кислоти піддають взаємодії з розчином бензолсульфонової кислоти або її амонієвої солі в інертному розчиннику.
UA4202353A 1986-04-04 1987-04-03 Спосіб одержання бензолсульфонатної солі 3-етіл-5метілового ефіру 2-(2-аміноетоксіметіл)-4-(2-хлорфеніл)-6-метіл-1,4-дігідропірідін-3,5-дікарбонової кислоти UA6344A1 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
UA6344A1 true UA6344A1 (uk) 1994-12-29

Family

ID=10595731

Family Applications (1)

Application Number Title Priority Date Filing Date
UA4202353A UA6344A1 (uk) 1986-04-04 1987-04-03 Спосіб одержання бензолсульфонатної солі 3-етіл-5метілового ефіру 2-(2-аміноетоксіметіл)-4-(2-хлорфеніл)-6-метіл-1,4-дігідропірідін-3,5-дікарбонової кислоти

Country Status (47)

Country Link
US (1) US4879303A (uk)
EP (1) EP0244944B1 (uk)
JP (1) JPS62240660A (uk)
KR (1) KR950006710B1 (uk)
CN (1) CN1023800C (uk)
AP (1) AP50A (uk)
AR (1) AR242562A1 (uk)
AT (1) ATE49752T1 (uk)
BE (1) BE1000130A4 (uk)
BG (1) BG60698B2 (uk)
CA (1) CA1321393C (uk)
CS (1) CS265237B2 (uk)
CY (1) CY1669A (uk)
CZ (1) CZ289095B6 (uk)
DD (1) DD265142A5 (uk)
DE (2) DE3710457A1 (uk)
DK (1) DK171708B1 (uk)
EC (1) ECSP941129A (uk)
EG (1) EG18266A (uk)
ES (2) ES2012803B3 (uk)
FI (1) FI85017C (uk)
FR (1) FR2596758B1 (uk)
GB (2) GB8608335D0 (uk)
GR (2) GR870525B (uk)
HK (1) HK76092A (uk)
HU (1) HU196962B (uk)
IE (1) IE59457B1 (uk)
IL (1) IL82101A (uk)
IN (1) IN168414B (uk)
IT (1) IT1203853B (uk)
LU (1) LU86812A1 (uk)
MA (1) MA20938A1 (uk)
MX (1) MX5847A (uk)
MY (1) MY101177A (uk)
NL (1) NL8700791A (uk)
NO (1) NO172181C (uk)
NZ (1) NZ219868A (uk)
PH (1) PH24348A (uk)
PL (1) PL149532B1 (uk)
PT (1) PT84611B (uk)
SE (1) SE463457B (uk)
SG (1) SG59692G (uk)
SK (1) SK278435B6 (uk)
SU (1) SU1498388A3 (uk)
UA (1) UA6344A1 (uk)
YU (1) YU44801B (uk)
ZA (1) ZA872439B (uk)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
JPH07501547A (ja) * 1991-11-26 1995-02-16 セプラコア，インコーポレーテッド 光学的に純粋な（−）アムロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JPH11500140A (ja) 1995-03-16 1999-01-06 ファイザー・インコーポレーテッド アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
WO1999018957A1 (en) * 1998-03-26 1999-04-22 Reddy-Cheminor, Inc. Stable pharmaceutical composition containing amlodipine besylate and atenolol
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
CN1234357C (zh) 1998-07-10 2006-01-04 诺瓦提斯公司 缬沙坦和钙通道阻断剂的抗超敏组合
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
ES2220426T3 (es) 1999-05-27 2004-12-16 Pfizer Products Inc. Profarmacos mutuos de amlodipino y atorvastatina.
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
UA72768C2 (en) 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
US6835742B2 (en) 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
CA2433284A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
WO2002053539A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amlodipine hemimaleate
GB2372036B (en) * 2000-12-29 2004-05-19 Bioorg Bv Aspartate derivative of amlodipine
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
BR0116557A (pt) * 2000-12-29 2003-10-28 Pfizer Ltd Processo, processo para fabricação de um sal de maleato de amlodipina substancialmente livre de aspartato de amlodipina, processo para purificação, maleato de amlodipina, composição farmacêutica para tratar ou prevenir angina ou hipertenção, método para tratar hipertenção, angina ou ataque cardìaco, benzeno sulfonato de amlodipina, hidrocloreto de amlodipina e uso de maleato de amlodipina substancialmente livre de aspartato de amlodipina
ATE356806T1 (de) * 2001-01-09 2007-04-15 Siegfried Generics Int Ag Salze von amlodipin-mesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
ATE454890T1 (de) * 2001-07-06 2010-01-15 Lek Pharmaceuticals Verfahren zur herstellung hochreines amlodipinbenzolsulfonat
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US6828339B2 (en) * 2001-11-21 2004-12-07 Synthon Bv Amlodipine salt forms and processes for preparing them
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
JP4287752B2 (ja) * 2002-04-13 2009-07-01 ハンリム ファーマシューティカル カンパニー リミテッド アムロジピンニコチネート及びその製造方法
CN100528241C (zh) 2002-05-06 2009-08-19 恩多塞特公司 维生素-定向的显象剂
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
KR100496436B1 (ko) 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
MXPA05002253A (es) 2002-08-29 2005-06-08 Taisho Pharma Co Ltd Sales bencenosulfonato de derivados de 4-fluoro-2-cianopirrolidina.
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
CN100420673C (zh) 2002-09-11 2008-09-24 韩林制药株式会社 S-(-)-氨氯地平烟酸盐及其制备方法
WO2004026834A1 (en) * 2002-09-19 2004-04-01 Cj Corporation Crystalline organic acid salt of amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (en) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research A process for the preparation of s (-) amlodipine salts
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
WO2004058711A1 (en) * 2002-12-30 2004-07-15 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
KR100558505B1 (ko) 2003-01-27 2006-03-07 한미약품 주식회사 안정한 무정형 암로디핀 캠실레이트, 이의 제조방법 및이를 포함하는 경구투여용 조성물
JP3874419B2 (ja) * 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
WO2004075825A2 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Dosage forms of amlodipine and processes for their preparation
DE04770646T1 (de) 2003-04-25 2011-12-08 Cadila Healthcare Ltd. Salze von clopidogrel und herstellungsverfahren
DE112004000712T5 (de) * 2003-04-25 2006-10-19 Cipla Ltd. Verfahren zur Herstellung von Amlodipinmesilat-Monohydrat
WO2004103959A2 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
JP4901474B2 (ja) 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060035940A1 (en) * 2004-03-16 2006-02-16 Sepracor Inc. (S)-Amlodipine malate
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
BRPI0514725A (pt) * 2004-08-30 2008-06-24 Seo Hong Yoo efeito neuroprotetor de udca solubilizado no modelo isquêmico focal
EP1809330B1 (en) * 2004-10-15 2011-04-27 Seo Hong Yoo Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin
EP2255812A1 (en) * 2004-11-01 2010-12-01 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
WO2006070248A1 (en) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
EP1898951B1 (en) * 2005-06-27 2013-02-27 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DK1797885T3 (da) * 2005-09-28 2008-07-14 Teva Pharma Stabil kombination af amlodipinbesylat og benazeprilhydrochlorid
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
KR20090048462A (ko) 2006-07-17 2009-05-13 라모트 앳 텔-아비브 유니버시티 리미티드 통증완화용 ｇａｂａ 접합체
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
WO2008076458A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
CN105152983A (zh) 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2009032286A2 (en) 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
KR101226669B1 (ko) * 2007-09-21 2013-01-25 한올바이오파마주식회사 Ｎ,ｎ－디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물
EP2240163A1 (en) 2007-12-31 2010-10-20 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2740017A1 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010070705A1 (ja) * 2008-12-17 2010-06-24 株式会社メドレックス アムロジピンの安定な含水経口製剤
WO2010085014A1 (en) 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
US8435562B2 (en) * 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EP2509603A1 (en) 2009-12-09 2012-10-17 Biolinerx Ltd. Methods of improving cognitive functions
PT3150610T (pt) 2010-02-12 2019-11-11 Pfizer Sais e polrmorfos de 8-fluor0-2-{4- [(metilamino}metil]fenil}-1,3,4,5-tetrahidr0-6hazepin0[ 5,4,3-cd]indol-6-0na
WO2011104637A2 (en) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
AU2011289604C1 (en) * 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
NZ609957A (en) 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
WO2012071524A1 (en) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
SG11201405692UA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Salts of an epidermal growth factor receptor kinase inhibitor
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
WO2014122585A1 (en) 2013-02-08 2014-08-14 Wockhardt Limited A stable pharmaceutical composition of amlodipine and benazepril or salts thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
US10420850B2 (en) 2015-08-14 2019-09-24 Endocyte, Inc. Method of imaging with a chelating agent
WO2017068532A1 (en) 2015-10-23 2017-04-27 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
JP6411662B2 (ja) 2016-05-30 2018-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 固定容量配合剤
EP3522872B1 (en) 2016-10-07 2021-08-11 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
WO2019200143A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN112955965B (zh) 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
WO2023285646A1 (en) 2021-07-15 2023-01-19 Adamed Pharma S.A A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
SE463457B (sv) 1990-11-26
YU44801B (en) 1991-02-28
GB8608335D0 (en) 1986-05-08
FI85017B (fi) 1991-11-15
MX5847A (es) 1993-08-01
NO172181B (no) 1993-03-08
BG60698B2 (en) 1995-12-29
AU7103087A (en) 1987-10-08
ATE49752T1 (de) 1990-02-15
GR3000394T3 (en) 1991-06-07
YU58087A (en) 1988-08-31
LU86812A1 (fr) 1987-08-12
US4879303A (en) 1989-11-07
ES2002599A6 (es) 1988-08-16
GB2188630B (en) 1990-04-04
CZ289095B6 (cs) 2001-10-17
HUT43821A (en) 1987-12-28
CN87102493A (zh) 1987-10-14
DK170187A (da) 1987-10-05
FR2596758B1 (fr) 1988-12-02
GR870525B (en) 1987-08-12
CS353991A3 (en) 1992-04-15
PT84611B (pt) 1989-11-30
EP0244944A3 (en) 1988-01-07
KR870009998A (ko) 1987-11-30
SE8701348L (sv) 1987-10-05
CY1669A (en) 1993-05-14
CS236387A2 (en) 1989-01-12
DK170187D0 (da) 1987-04-03
PL264982A1 (en) 1988-05-26
BE1000130A4 (fr) 1988-04-12
FI85017C (fi) 1992-02-25
DE3761485D1 (de) 1990-03-01
AU573123B2 (en) 1988-05-26
PL149532B1 (en) 1990-02-28
DE3710457A1 (de) 1987-10-08
PT84611A (en) 1987-05-01
ES2012803B3 (es) 1990-04-16
IT8719977A0 (it) 1987-04-03
IL82101A (en) 1991-01-31
IT1203853B (it) 1989-02-23
NO871408D0 (no) 1987-04-03
SK278435B6 (en) 1997-05-07
NO871408L (no) 1987-10-05
PH24348A (en) 1990-06-13
JPH037668B2 (uk) 1991-02-04
MA20938A1 (fr) 1987-12-31
KR950006710B1 (ko) 1995-06-21
DD265142A5 (de) 1989-02-22
FI871470A0 (fi) 1987-04-03
NL8700791A (nl) 1987-11-02
AP50A (en) 1989-09-16
CS265237B2 (en) 1989-10-13
SE8701348D0 (sv) 1987-03-31
IL82101A0 (en) 1987-10-30
ZA872439B (en) 1988-11-30
SG59692G (en) 1992-12-04
CA1321393C (en) 1993-08-17
NO172181C (no) 1993-06-16
FR2596758A1 (fr) 1987-10-09
EP0244944A2 (en) 1987-11-11
GB8707653D0 (en) 1987-05-07
HK76092A (en) 1992-10-09
ECSP941129A (es) 1994-12-15
AR242562A1 (es) 1993-04-30
JPS62240660A (ja) 1987-10-21
EG18266A (en) 1992-12-30
DK171708B1 (da) 1997-04-01
FI871470A (fi) 1987-10-05
HU196962B (en) 1989-02-28
AP8700060A0 (en) 1987-02-01
IE870869L (en) 1987-10-04
SU1498388A3 (ru) 1989-07-30
GB2188630A (en) 1987-10-07
EP0244944B1 (en) 1990-01-24
IN168414B (uk) 1991-03-30
IE59457B1 (en) 1994-02-23
MY101177A (en) 1991-07-31
NZ219868A (en) 1989-02-24
CN1023800C (zh) 1994-02-16

Similar Documents

Publication Publication Date Title
UA6344A1 (uk) Спосіб одержання бензолсульфонатної солі 3-етіл-5метілового ефіру 2-(2-аміноетоксіметіл)-4-(2-хлорфеніл)-6-метіл-1,4-дігідропірідін-3,5-дікарбонової кислоти
GB2164336B (en) 4-aryl-1,4-dihydropyridine-3,5-dicarboxylate derivatives
DE3580293D1 (de) Ungesaettigte amido-substituierte cyclische aethern-verbindungen und verfahren zu ihrer herstellung.
DE3378532D1 (en) 1,4-dihydropyridine-3,5-dicarboxylic acid ester derivatives
DE3882055D1 (de) Verfahren zur herstellung von pyridin-2,3-dicarboxylsaeure-verbindungen.
ATE150456T1 (de) Verfahren zur herstellung von an 4-position substituierten 1,4-dihydropyridinen
HUT47250A (en) Process for producing pyridine-2,4- and -2,5-dicarboxylic acid derivatives and pharmaceuticals comprising such compounds
PT81116B (en) Process for preparing 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives
DE3869147D1 (de) Copolymer von vinylidenfluorid-acrylsaeureester, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung.
HUT47249A (en) Process for producing pyridine-2,4- and -2,5-dicarboxylic acid derivatives and pharmaceuticals comprising such compounds
EP0168789A3 (en) Method for preparing unsymmetrical 1,4-dihydropyridine-3,5-dicarboxylic acid diesters
DK209289A (da) Fremgangsmaade til fremstilling af indol-3-carboxylsyreestere af trans-hexahydro-8-hydroxy-2,6-methano-2h-quinolin-3(4h)-on
DK306388D0 (da) Fremgangsmaade til fremstilling af l-askorbinsyre
AU507892B2 (en) 1, 4-Dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3, 5 pyridine dicarboxylic acid isopropyl, 2-propoxyethy1 esters
DK468385A (da) Fremgangsmaade til fremstilling af den optiske d-isomer af diastereomeren aeaae af 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylsyre-3-(1-benzylpyrrolidin-3-yl)-ester-5-methylester
PT83674B (en) Process for preparing 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives
ATE182140T1 (de) Optisch aktive 1,4-dihydropyridinderivate sowie verfahren zu ihrer herstellung
DK165686A (da) 1,4-dihydropyridin-3,5-dicarboxylatderivater
LV5619A3 (lv) Panemiens 2-(2-aminoetoksimetil)-4-(2-hlorfenil)-6-metil-1,4-dihidropiridina-3,5-dikarbonskabes 3-etil-5-metilestera benzolsulfoskabes sais iegusanai
HRP950452B1 (en) Process for the preparation of benzosulphonate salts 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)1,4-dihydro-6-methylpyridine -3,5-dicarboxylate
EP0311053A3 (en) Ameliorant of cerebral circulation and optical isomer of nb-818, processes for its production and its use
DK158462C (da) Fremgangsmaade til fremstilling af 3-alkoxy- eller 3,3-dialkoxycarboxylsyreestere
GB2180532B (en) Alkoxy-and phenoxy-alkyl-esters of 2,6-dimethyl-4-(2-difluoromethoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid
DE68923232D1 (de) Verfahren zur herstellung von pyridin-2,3-dicarbonsäure-verbindungen.
AU7594887A (en) 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid derivatives